Pacira assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Pacira (PCRX) with a Buy rating and $38 price target The firm thinks the enactment of the NOPAIN Act removes any barriers to access in the key surgical procedures in which Pacira’s Exparel is best suited. In addition, the approval for nerve blocks should drive consistent clinical performance and removes “technique” sensitivity, the analyst tells investors in a research note.